Implications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts).
Zengin Z, Henderson N, Park J, Ali A, Hwang C, Barata P, Bilen M, Graham L, Kilari D, Tripathi A, Labriola M, Rothstein S, Garje R, Koshkin V, Patel V, Schweizer M, Armstrong A, McKay R, Alva A, Dorff T. Implications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts). Journal Of Clinical Oncology 2022, 40: 138-138. DOI: 10.1200/jco.2022.40.6_suppl.138.Peer-Reviewed Original ResearchAR alterationsAR mutationsGenomic testingAdvanced prostate cancer patientsAndrogen receptor alterationsKaplan-Meier methodLog-rank testProstate cancer patientsAlteration statusMedian TTPPSA declineCastration resistancePSA responseMedian ageAR amplificationDocetaxel exposureReceptor alterationsStratified patientsTestosterone suppressionShorter TTPCancer patientsTreatment outcomesAbirateroneCastration statusDomain mutations